Test-retest reliability of Brazilian version of Memorial Symptom Assessment Scale for assessing symptoms in cancer patients

Menezes, Josiane Roberta de; Luvisaro, Bianca Maria Oliveira; Rodrigues, Claudia Fernandes; Muzi, Camila Drumond; Guimarães, Raphael Mendonça

doi:10.1590/s1679-45082017ao3645

Cited by 13 publications

(9 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This fact, when observed in the oral cavity, on average from the 7th to the 10th day after the administration of chemotherapy, presents a predisposition to the appearance of dry mouth and oral infections such as candidiasis, in addition to halitosis, the appearance of lesions, burning mouth, difficulties in chewing, swallowing and speech, as well as decreased taste. All of this has consequences for general health, such as poor nutrition, problems in social relationships and sleep, compromising quality of life (5,(7)(8)(9) .…”

Section: Introductionmentioning

confidence: 99%

Prevalence of xerostomia in women during breast cancer chemotherapy

et al. 2020

View full text Add to dashboard Cite

Objective: To identify the prevalence of xerostomia in women undergoing chemotherapy for breast cancer. Method: Prospective cohort with 27 women who underwent up to 16 sessions of intravenous chemotherapy. Data collection was performed at the outpatient clinic of a university hospital in the city of São Paulo, where two forms were applied before the start of treatment and the Xerostomia Inventory before and after each chemotherapy session. Results: Complaints of dry mouth were present in 48.1% of women before chemotherapy, and they were approximately 28 times more likely to develop dry mouth during treatment. It was observed that the use of antiemetics contributed to the occurrence of xerostomia, and the anti-ulcerous were presented as a protective factor. Conclusion: The study identified both a high prevalence of xerostomia regardless of the chemotherapy used and the need to create protocols to improve the quality of life of these patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Prevalence of xerostomia in women during breast cancer chemotherapy

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Among the most widely used scales to assess these symptoms is the MSAS. Many authors have validated this scale in their respective countries and languages [ 15 , 16 , 17 , 18 , 19 , 20 , 21 ]. In all of them, the MSAS has proved to be valid and reliable.…”

Section: Discussionmentioning

confidence: 99%

“…Therefore, among the validated MSAS versions collected in the literature, “lack of energy” seems to represent a higher prevalence for the US version [ 14 ], the Arabic version [ 17 ], the Spanish version [ 19 ], and for the Colombian sample presented in this study, with 68.7% prevalence. Furthermore, it turned out to be the second most prevalent symptom for the Chinese [ 15 ], Turkish [ 16 ], Hebrew [ 18 ], and Brazilian versions [ 20 ]. Another of the most prevalent symptoms has been “dry mouth”, representing the first place for the Chinese [ 15 ] and Brazilian [ 20 ] versions, with 57.3% and 61.58% prevalence, respectively.…”

Section: Discussionmentioning

confidence: 99%

“…The MSAS has been extensively investigated in recent years. Several authors have adapted and translated this scale into other languages, such as Cheng et al [ 15 ], who developed the Chinese version (2009); Yildirim et al [ 16 ], the Turkish version (2011); Abu-Saad et al [ 17 ], the Arabic version (2014); Pud [ 18 ], the Hebrew version (2015); Llamas-Ramos et al [ 19 ], the Spanish version (2016); Menezes et al [ 20 ], the Brazilian version (2017); and Haryani et al [ 21 ], the Indonesian version (2018). All these translations correspond to the original MSAS, but it is worth mentioning that this scale has two further versions: the MSAS Short Form and the MSAS Condensed Form, both created by Chang et al, in 2000 [ 22 ] and 2004 [ 23 ], respectively.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Symptom Prevalence in Spanish and Colombian Oncology Patients Measured with the MSAS

Llamas-Ramos

González

et al. 2022

Cancers

View full text Add to dashboard Cite

Cancer patients experience several symptoms throughout their illness and the treatments they receive. While this pathology represents a worldwide health problem, knowing the symptom prevalence in oncology patients remains a challenge; validated tools to obtain this information are essential. Furthermore, this prevalence information would help health professionals to establish appropriate treatments. The objective of this study was to ascertain the symptom prevalence in cancer patients from Spain and Colombia to improve future approaches. The frequency, severity, and distress of 32 symptoms from a validated scale experienced by cancer patients from Spain and Colombia were measured. Two hundred and forty-six patients (49.7%) who attended the Day University Hospital of Salamanca (Spain) and two hundred and forty-nine outpatients (50.3%) of the San Diego Cancer Center (Colombia) between 2016 and 2019 participated in the study. All patients filled in the Assessment Scale only once. Four hundred and ninety-five patients (333 women (67.3%) and 162 men (32.7%)) completed the Memorial Symptom Assessment Scale (Spanish version). The most frequent symptom for both samples (Spanish and Colombian) was “lack of energy” (38.4% and 13.7%, respectively). The most severe symptoms for the Spanish and Colombian samples were “problems with sexual interest or activity” (38.4%) and “dry mouth” (13.7%), respectively, and both samples agreed on the most distressing symptom: “hair loss” (Spanish, 38%; Colombian, 10.1%). The Spanish version of the MSAS has proven to be a valid and reliable tool in Spanish-speaking countries to obtain the most prevalent, severe, and distressing symptoms in Spanish and Colombian oncology patients. The prevalence of symptoms was demonstrated to be similar across both countries, and the results will help to design and adapt treatments for cancer patients, targeting these symptoms to reduce or avoid them and thus improving their quality of life.

show abstract

“…The Memorial Symptom Assessment Scale (MSAS) has been widely used as a self-report questionnaire to measure the multidimensional experience of symptoms. 15,16 Our research team referred to the MSAS scale and other symptom assessment and quality of life scales, on the basis of which the CPSAS was established. 12 As reported in previous articles, the CPSAS has been verified to have good reliability and validity.…”

Section: Methodsmentioning

confidence: 99%

Symptom clusters in patients with colorectal cancer after colostomy: a longitudinal study in Shanghai

Hao

Liu

et al. 2021

J Int Med Res

View full text Add to dashboard Cite

Objective Research is lacking regarding the experiences of patients after colostomy, which is needed so as to take necessary specific actions. In this study, we aimed to describe the trajectory of symptom clusters experienced by patients after colostomy over time. Methods This was a longitudinal observational study using data from 149 patients with colorectal cancer after colostomy. We investigated symptoms and symptom clusters at 2 weeks, 1 month, 3 months, 6 months, and 1 year after colostomy. Results Four main symptom clusters were identified, including a psychological symptom cluster, digestive and urinary symptom cluster, lack of energy symptom cluster, and pain symptom cluster in patients after colostomy in the first year after surgery. We further explored the symptom trajectory. Conclusions We explored symptom clusters and the trajectory of symptom resolution in patients after colostomy during the first year after surgery. Four stages were proposed to describe the different statuses of symptom clusters experienced by patients. Our findings may provide insight into how to improve symptom management and postoperative quality of life for patients after colostomy.

show abstract

Test-retest reliability of Brazilian version of Memorial Symptom Assessment Scale for assessing symptoms in cancer patients

Cited by 13 publications

References 15 publications

Prevalence of xerostomia in women during breast cancer chemotherapy

Prevalence of xerostomia in women during breast cancer chemotherapy

Symptom Prevalence in Spanish and Colombian Oncology Patients Measured with the MSAS

Symptom clusters in patients with colorectal cancer after colostomy: a longitudinal study in Shanghai

Contact Info

Product

Resources

About